Robert Gross1, Scarlett L Bellamy, Bakgaki Ratshaa, Xiaoyan Han, Marijana Vujkovic, Richard Aplenc, Andrew P Steenhoff, Mosepele Mosepele, Ganesh Moorthy, Athena F Zuppa, Brian L Strom, Gregory P Bisson. 1. aDepartments of Medicine (Infectious Diseases) bEpidemiology cCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia dDepartment of Epidemiology and Biostatistics, Drexel University Dornsife School of Public Health, Philadelphia, Pennsylvania eBotswana -UPenn Partnership, Gaborone, Botswana fDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania gFaculty of Medicine, University of Botswana, Gaborone, Botswana hOffice of the Chancellor, Rutgers Biomedical and Health Sciences, Rutgers University New Brunswick, New Jersey, USA.
Abstract
OBJECTIVES: To determine the association between cytochrome p450 2B6 genotypes and efavirenz-based HIV treatment outcomes. DESIGN: Observational cohort study of HIV-infected adults initiating efavirenz-based regimens in Botswana. METHODS: The primary endpoint was a composite of death or loss to care or HIV RNA more than 25 copies/ml at 6 months. CYP2B6 516G>T and 983T>C genotyping was done with Taqman Open Array platform. Adverse experiences were measured by using the Subject Experience Questionnaire. Metabolism alleles were included in logistic regression models of the composite endpoint. RESULTS: A total of 801 individuals included 406 (51%) men, median age 37 years, median baseline CD4 cell count 195 cells/μl, and plasma HIV RNA 4.9 log10 copies/ml. 288 (36%) reached the endpoint, including 34 (4%) deaths, 151 (19%) lost to care, 11 (1%) lost to the study, but alive and in care, and 92 (11%) with plasma HIV RNA more than 25 copies/ml. Metabolism variant alleles were common with 396 (49%) intermediate and 192 (24%) slow metabolizers. There were no statistically significant associations between metabolism and treatment endpoints. However, slower metabolism was associated with fewer adverse experiences. CONCLUSION: Slow metabolism alleles were associated with lower efavirenz clearance but not any of the treatment endpoints. Slow efavirenz metabolism did not exacerbate central nervous system toxicity. These results should allay concern that slow efavirenz metabolism adversely impacts individuals in sub-Saharan African settings in which these alleles are common.
OBJECTIVES: To determine the association between cytochrome p450 2B6 genotypes and efavirenz-based HIV treatment outcomes. DESIGN: Observational cohort study of HIV-infected adults initiating efavirenz-based regimens in Botswana. METHODS: The primary endpoint was a composite of death or loss to care or HIV RNA more than 25 copies/ml at 6 months. CYP2B6 516G>T and 983T>C genotyping was done with Taqman Open Array platform. Adverse experiences were measured by using the Subject Experience Questionnaire. Metabolism alleles were included in logistic regression models of the composite endpoint. RESULTS: A total of 801 individuals included 406 (51%) men, median age 37 years, median baseline CD4 cell count 195 cells/μl, and plasma HIV RNA 4.9 log10 copies/ml. 288 (36%) reached the endpoint, including 34 (4%) deaths, 151 (19%) lost to care, 11 (1%) lost to the study, but alive and in care, and 92 (11%) with plasma HIV RNA more than 25 copies/ml. Metabolism variant alleles were common with 396 (49%) intermediate and 192 (24%) slow metabolizers. There were no statistically significant associations between metabolism and treatment endpoints. However, slower metabolism was associated with fewer adverse experiences. CONCLUSION: Slow metabolism alleles were associated with lower efavirenz clearance but not any of the treatment endpoints. Slow efavirenz metabolism did not exacerbate central nervous system toxicity. These results should allay concern that slow efavirenz metabolism adversely impacts individuals in sub-Saharan African settings in which these alleles are common.
Authors: David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta Journal: AIDS Date: 2004-12-03 Impact factor: 4.177
Authors: Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey Journal: J Pharmacol Exp Ther Date: 2012-09-13 Impact factor: 4.030
Authors: Robert Gross; Richard Aplenc; Thomas Tenhave; Andrea S Foulkes; Rameshwari Thakur; Mosepele Mosepele; Jeffrey S Barrett; Charles Flexner; Brian L Strom; Gregory Bisson Journal: J Acquir Immune Defic Syndr Date: 2008-11-01 Impact factor: 3.731
Authors: Matthias Egger; Ben D Spycher; John Sidle; Ralf Weigel; Elvin H Geng; Matthew P Fox; Patrick MacPhail; Gilles van Cutsem; Eugène Messou; Robin Wood; Denis Nash; Margaret Pascoe; Diana Dickinson; Jean-François Etard; James A McIntyre; Martin W G Brinkhof Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Leigh F Johnson; Joel Mossong; Rob E Dorrington; Michael Schomaker; Christopher J Hoffmann; Olivia Keiser; Matthew P Fox; Robin Wood; Hans Prozesky; Janet Giddy; Daniela Belen Garone; Morna Cornell; Matthias Egger; Andrew Boulle Journal: PLoS Med Date: 2013-04-09 Impact factor: 11.069
Authors: Nathan W Cummins; Jacqueline Neuhaus; Haitao Chu; James Neaton; Christoph Wyen; Jürgen K Rockstroh; Daniel J Skiest; Mark A Boyd; Saye Khoo; Margalida Rotger; Amalio Telenti; Richard Weinshilboum; Andrew D Badley Journal: EBioMedicine Date: 2015-05-12 Impact factor: 8.143
Authors: Jonathan L Chang; Alexander C Tsai; Nicholas Musinguzi; Jessica E Haberer; Yap Boum; Conrad Muzoora; Mwebesa Bwana; Jeffrey N Martin; Peter W Hunt; David R Bangsberg; Mark J Siedner Journal: Ann Intern Med Date: 2018-06-26 Impact factor: 25.391
Authors: Jonathan L Chang; Sulggi A Lee; Alexander C Tsai; Nicholas Musinguzi; Conrad Muzoora; Bosco Bwana; Yap Boum; Jessica E Haberer; Peter W Hunt; Jeff Martin; David R Bangsberg; Deanna L Kroetz; Mark J Siedner Journal: AIDS Res Hum Retroviruses Date: 2018-08-15 Impact factor: 2.205
Authors: Leah H Rubin; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Sarah M Lofgren; David R Boulware; Raha Dastgheyb; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: J Neurovirol Date: 2019-06-19 Impact factor: 2.643
Authors: Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas Journal: Clin Pharmacol Ther Date: 2019-07-05 Impact factor: 6.875
Authors: Marijana Vujkovic; Scarlett L Bellamy; Athena F Zuppa; Marc R Gastonguay; Ganesh S Moorthy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Brian L Strom; Gregory P Bisson; Richard Aplenc; Robert Gross Journal: Pharmacogenomics J Date: 2018-06-01 Impact factor: 3.550
Authors: Rolando Garza; Alexander J Gill; Brandon L Bastien; Yoelvis Garcia-Mesa; Analise L Gruenewald; Benjamin B Gelman; Billy Tsima; Robert Gross; Scott L Letendre; Dennis L Kolson Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-04-10
Authors: Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Kaelo K Seatla; Sikhulile Moyo; Axel Martinelli; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti Journal: Pharmgenomics Pers Med Date: 2021-03-16